Unicycive Therapeutics annual operating expenses
2020
2021
2022
2023
2024
2025
Unicycive Therapeutics Operating Expenses Growth & History (UNCY)
Unicycive Therapeutics's operating expenses was $29.5M for fiscal 2025.
View full Unicycive Therapeutics company overviewUnicycive Therapeutics annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $29.5M | −$2.6M | −8.10% |
| 2024 | 2024-12-31 | $32.1M | $10.7M | +49.74% |
| 2023 | 2023-12-31 | $21.4M | $2.4M | +12.87% |
| 2022 | 2022-12-31 | $19.0M | $10.0M | +111.69% |
| 2021 | 2021-12-31 | $9.0M | $7.0M | +344.41% |
| 2020 | 2020-12-31 | $2.0M | — | — |
Unicycive Therapeutics quarterly operating expenses
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $10.1M | $3.2M | +45.63% |
| Q1 2026 | 2026-03-31 | $8.4M | $448,000 | +5.61% |
| Q4 2025 | 2025-12-31 | $7.2M | −$2.0M | −22.01% |
| Q3 2025 | 2025-09-30 | $7.3M | $1.1M | +17.45% |
| Q2 2025 | 2025-06-30 | $7.0M | −$438,000 | −5.92% |
| Q1 2025 | 2025-03-31 | $8.0M | −$1.2M | −13.20% |
| Q4 2024 | 2024-12-31 | $9.3M | $2.9M | +46.72% |
| Q3 2024 | 2024-09-30 | $6.3M | $313,000 | +5.27% |
| Q2 2024 | 2024-06-30 | $7.4M | $3.1M | +71.24% |
| Q1 2024 | 2024-03-31 | $9.2M | $4.3M | +88.72% |
| Q4 2023 | 2023-12-31 | $6.3M | $987,000 | +18.54% |
| Q3 2023 | 2023-09-30 | $5.9M | −$567,000 | −8.72% |
| Q2 2023 | 2023-06-30 | $4.3M | $686,000 | +18.87% |
| Q1 2023 | 2023-03-31 | $4.9M | $1.3M | +37.89% |
| Q4 2022 | 2022-12-31 | $5.3M | $2.6M | +93.50% |
| Q3 2022 | 2022-09-30 | $6.5M | $1.8M | +37.96% |
| Q2 2022 | 2022-06-30 | $3.6M | $2.9M | +366.75% |
| Q1 2022 | 2022-03-31 | $3.5M | $2.8M | +383.86% |
| Q4 2021 | 2021-12-31 | $2.8M | — | — |
| Q3 2021 | 2021-09-30 | $4.7M | $4.1M | +653.19% |
| Q2 2021 | 2021-06-30 | $779,000 | $443,000 | +131.85% |
| Q1 2021 | 2021-03-31 | $731,000 | — | — |
| Q3 2020 | 2020-09-30 | $626,000 | — | — |
| Q2 2020 | 2020-06-30 | $336,000 | — | — |
Unicycive Therapeutics operating expenses trends
Over the last five fiscal years, Unicycive Therapeutics's operating expenses increased from $2.0M to $29.5M, a change of $27.5M. The latest reported quarter, Q2 2026, shows $10.1M.
About the metric
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
Calculation and source
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Unicycive Therapeutics source filings ↗